Changing Standards and Evolving Strategies in AML Patients Unfit for Intensive Chemotherapy

References

1. Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. *Blood.* 2022 Sep 15;140(11):1200-1228. doi: 10.1182/blood.2022015850. PMID: 35767897; PMCID: PMC9479031.

2. Haferlach T, Bacher U, Alpermann T, et al. Prognosis in patients with MDS or AML and bone marrow blasts between 10% and 30% is not associated with blast count but depends on cytogenetic and molecular genetic parameters. *Blood*. 2010;116(21):2703. doi: https://doi.org/10.1182/blood.V116.21.2703.2703

3. Bill M, Eckardt J-N, Rausch C, et al. Secondary-type mutations do not impact the favorable outcome of NPM1-mutated acute myeloid leukemia patients – results from a large cohort of intensively treated patients. Abstract presented at ASH Annual Meeting. San Diego, CA. December 11, 2023.

4. Eckardt J-N, Bill M, Rausch C, et al. Secondary-type mutations do not impact outcome in *NPM1*-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification. *Leukemia*. 2023;37:2282–2285. https://doi.org/10.1038/s41375-023-02016-6

5. Lachowiez CA, Asimomitis G, Bernard E, et al. The significance of variant allele frequency in *SF3B1* mutated myelodysplastic neoplasms/syndromes. *Blood*. 2023;142(Suppl 1):1870. doi: https://doi.org/10.1182/blood-2023-179899

6. Daver NG, Vyas P, Kambhampati S, et al. Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results. *J Clin Oncol.* 2022;40:7020.DOI:10.1200/JCO.2022.40.16_suppl.7020

7. Moreno Vanegas Y, Badar T. Clinical utility of azacitidine in the management of acute myeloid leukemia: update on patient selection and reported outcomes. *Cancer Manag Res.* 2022 Dec 23;14:3527-3538. doi: 10.2147/CMAR.S271442. PMID: 36583031; PMCID: PMC9793740.

8. Patel P, Ruppert AS, Borate U, Stein EM, et al. Ivosidenib (IVO) in combination with azacitidine (AZA) in newly diagnosed (ND) older patients with IDH1 R132-mutated acute myeloid leukemia (AML) induces high response rates: a phase 2 sub-study of the Beat AML Master Trial. *Blood*. 2021; 138(Suppl 1):875. doi: https://doi.org/10.1182/blood-2021-149115

9. Cortes J, Jurcic J, Baer MR, et al. Olutasidenib for the treatment of mIDH1 acute myeloid leukemia in patients relapsed or refractory to hematopoietic stem cell transplant, prior mIDH1 inhibitor, or venetoclax. *Blood*.2023;142(Supplement 1): 2888. doi: https://doi.org/10.1182/blood-2023-187861

10. Hammond D, Loghavi S, Wang SS, et al. Response patterns and impact of MRD in patients with *IDH1/2*-mutated AML treated with venetoclax and hypomethylating agents. *Blood Cancer J.* 2023;13:148. https://doi.org/10.1038/s41408-023-00915-6

11. Molica M, Mazzone C, Niscola P, de Fabritiis P. *TP53* Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge? *Front Oncol.* 2021 Feb 8;10:610820. doi: 10.3389/fonc.2020.610820. PMID: 33628731; PMCID: PMC7897660.

12. Short NJ, DiNardo CD, Daver N, et al. A triplet combination of azacitidine, venetoclax and gilteritinib for patients with *FLT3*-mutated acute myeloid leukemia: results from a phase I/II study. *Blood*. 2021;138(Supplement 1):696. doi: https://doi.org/10.1182/blood-2021-153571

13. Yilmaz M, Muftuoglu M, Kantarjian H, et al. Quizartinib (Quiz) with Decitabine (DAC) and Venetoclax (VEN) Is Highly Active in Patients (pts) with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) - RAS/MAPK Mutations Continue to Drive Primary and Secondary Resistance. *Blood*. 2021;138 (Supplement 1):370. doi: https://doi.org/10.1182/blood-2021-153426

14. Stengel A, Meggendorfer M, Walter W, et al. Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS. *Blood Adv.* 2023 Sep 26;7(18):5540-5548. doi: 10.1182/bloodadvances.2023010312. PMID: 37505914; PMCID: PMC10515307.

15. Stengel A, Haferlach T, Baer C, et al. Specific subtype distribution with impact on prognosis of *TP53* single-hit and double-hit events in AML and MDS. *Blood Adv*. 2023;7(13):2952–2956. doi: https://doi.org/10.1182/bloodadvances.2022009100

16. Seiter K, Germani S, Martin J, et al. CLAG-Based Induction Therapy in Previously Untreated High Risk AML Patients. *Blood*. 2015;126(23):4892. doi: https://doi.org/10.1182/blood.V126.23.4892.4892

17. Tran V, Bouligny IM, Murray G, et al. FLAG-IDA or venetoclax in previously treated TP53mut acute myeloid leukemia. *J Clin Oncol. 2023;*41:e19047-e19047. doi:10.1200/JCO.2023.41.16_suppl.e19047

18. Fitzpatrick MJ, Boiocchi L, Fathi AT, et al. Correlation of p53 immunohistochemistry with TP53 mutational status and overall survival in newly diagnosed acute myeloid leukaemia. *Histopathology.* 2022 Oct;81(4):496-510. doi: 10.1111/his.14726. Epub 2022 Aug 7. PMID: 35869818.

19. George B, Kantarjian H, Baran N, et al. *TP53* in Acute myeloid leukemia: molecular aspects and patterns of mutation. *Int J Mol Sci.* 2021 Oct 5;22(19):10782. doi: 10.3390/ijms221910782. PMID: 34639121; PMCID: PMC8509740.

20. Martin-Cabrera P, Jeromin S, Perglerovà K, et al. Acute myeloid leukemias with ring sideroblasts show a unique molecular signature straddling secondary acute myeloid leukemia and *de novo* acute myeloid leukemia. *Haematologica.* 2017 Apr;102(4):e125-e128. doi: 10.3324/haematol.2016.156844. Epub 2017 Jan 5. PMID: 28057736; PMCID: PMC5395122.

21. Short NJ, Kantarjian H. When Less Is More: Reevaluating the role of intensive chemotherapy for older adults with acute myeloid leukemia in the modern era. *J Clin Oncol.* 2021 Oct 1;39(28):3104-3108. doi: 10.1200/JCO.21.00960. Epub 2021 Aug 18. PMID: 34406793; PMCID: PMC8478366.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Pfizer, Inc.

